Table 1.
Baseline demographics and disease characteristics.
| Without liver metastases (n = 23) | With liver metastases (n = 47) | All patients (N = 70) | |
|---|---|---|---|
| Baseline demographics | |||
| Male sex, n (%) | 9 (39) | 32 (68) | 41 (59) |
| Female sex, n (%) | 14 (61) | 15 (32) | 29 (41) |
| Median age, years (IQR) | 57 (51–66) | 56 (50–66) | 57 (50–66) |
| Race, n (%) | |||
| White | 16 (70) | 34 (72) | 50 (71) |
| Black or African American | 2 (9) | 8 (17) | 10 (14) |
| Asian | 4 (17) | 3 (6) | 7 (10) |
| Native Hawaiian or other Pacific Islander | 0 | 1 (2) | 1 (1) |
| Not reported | 1 (4) | 1 (2) | 2 (3) |
| ECOG PS, n (%) | |||
| 0 | 14 (61) | 22 (47) | 36 (51) |
| 1 | 9 (39) | 25 (53) | 34 (49) |
| Primary cancer site, n (%) | |||
| Right colon | 6 (26) | 19 (40) | 25 (36) |
| Left colon and rectum | 17 (74) | 28 (60) | 45 (64) |
| Disease characteristics | |||
| Liver metastases at baseline, n (%) | 0 | 47 (100) | 47 (67) |
| Lung metastases at baseline, n (%) | 16 (70) | 35 (74) | 51 (73) |
| Peritoneal metastases at baseline, n (%) | 2 (9) | 4 (9) | 6 (9) |
| Mutation status, n (%) | |||
| BRAF, KRAS, and NRAS wild type | 7 (30) | 15 (32) | 22 (31) |
| KRAS or NRAS mutation | 14 (61) | 29 (62) | 43 (61) |
| BRAF mutation | 2 (9) | 1 (2) | 3 (4) |
| Could not be evaluated for BRAF, KRAS, or NRAS | 0 | 2 (4) | 2 (3) |
| Histology, n (%) | |||
| Adenocarcinoma, not otherwise specified | 22 (96) | 43 (91) | 65 (93) |
| Mucinous adenocarcinoma | 1 (4) | 4 (9) | 5 (7) |
| Number of previous anti-cancer regimens,a n (%) | |||
| 1 | 1 (4) | 2 (4) | 3 (4) |
| 2 | 8 (35) | 22 (47) | 30 (43) |
| 3 | 6 (26) | 12 (26) | 18 (26) |
| ≥4 | 8 (35) | 11 (23) | 19 (27) |
| Previous anti-cancer therapy, n (%) | 23 (100) | 47 (100) | 70 (100) |
| Fluoropyrimidines | 23 (100) | 47 (100) | 70 (100) |
| Oxaliplatin | 22 (96) | 47 (100) | 69 (99) |
| Irinotecan | 23 (100) | 47 (100) | 70 (100) |
| Anti-VEGF | 23 (100) | 43 (91) | 66 (94) |
| EGFR inhibitors | 10 (43) | 13 (28) | 23 (33) |
| Napabucasin | 1 (4) | 0 | 1 (1) |
| Prior radiotherapy, n (%) | 8 (35) | 9 (19) | 17 (24) |
| Median time from diagnosis of metastases, months (IQR) | 33 (23–47) | 21 (13–32) | 24 (15–36) |
ECOG PS = Eastern Cooperative Oncology Group performance status; EGFR = epidermal growth factor receptor; IQR = interquartile range; VEGF = vascular endothelial growth factor.
a
All regimens are counted, including neoadjuvant, adjuvant, and repeated regimens. Neoadjuvant and adjuvant regimens are not considered a previous line of therapy unless there was recurrence within 6 months. Repetition of a regimen is not considered a different line of therapy.